USA flag logo/image

An Official Website of the United States Government

Development of Non-Narcotic Intravenous Analgesics

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
85905
Program Year/Program:
2007 / SBIR
Agency Tracking Number:
NS051880
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
ST. CHARLES PHARMACEUTICALS
650 Poydras St, Suite 2830 New Orleans, LA 70130
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2007
Title: Development of Non-Narcotic Intravenous Analgesics
Agency: HHS
Contract: 1R43NS051880-01A2
Award Amount: $111,893.00
 

Abstract:

DESCRIPTION (provided by applicant): Intravenous drug administration is often clinically desired over oral administration, particularly for patients who have difficulty taking an oral drug due to their disease or condition (eg, unconsciousness, anesthetize d). IV administration also produces a faster therapeutic onset and permits more accurate dose administration and titration. Although variables related to drug absorption are circumvented by IV administration, IV drugs must have good water solubility to avo id issues related to blood clotting and formation of embolisms. Therefore, the solubility characteristics of new drug candidates have a significant effect on their chance for therapeutic (and commercial) success. We have been exploring a series of new and proprietary analogs of acetaminophen that show good oral efficacy but are devoid of hepatotoxic effects. Under this Phase I project we will prepare water-soluble analogs of these compounds, and determine the feasibility for further development of each of t hese target-candidate compounds as IV analgesics. This technology will fulfill one of our target profiles, defined as a drug that is clinically useful as an IV treatment for postoperative pain and other types of pain, including patients that may have compr omised liver function (eg. elderly, cancer patients, and patients with alcoholic liver injury or hepatitis).

Principal Investigator:

Kenneth W. Narducy
5045688524
KNARDUCY@MSN.COM

Business Contact:

Kenneth Narducy
knarducy@msn.com
Small Business Information at Submission:

ST. CHARLES PHARMACEUTICALS
650 Poydras St, Suite 2830 New Orleans, LA 70130

EIN/Tax ID: 721438669
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No